Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty

Annual Review of Medicine

Volumn 51, Issue , 2000, Pages 245-270

  Ershler, William B ^a   Keller, Evan T ^b  

^a Inst for the Adv Studs in Aging   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cachexia; Cytokines; Dementia; Immune dysregulation; Immunodeficiency; Osteoporosis; Sarcopenia

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; ESTROGEN; INTERLEUKIN 6; SERUM ALBUMIN; SERUM AMYLOID A; TESTOSTERONE;

AGE; ANEMIA; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATORY DISEASE; LEAN BODY WEIGHT; OSTEOPENIA; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW;

AGE FACTORS; AGED; AGING; ALZHEIMER DISEASE; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-6; LYMPHOPROLIFERATIVE DISORDERS; OSTEOPOROSIS; RECEPTORS, INTERLEUKIN-6;

EID: 0034051068     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.51.1.245     Document Type: Review

References (197)

1. 1. Ershler WB. 1993. Interleukin-6: a cytokine for gerontologists. J. Am. Geriatr. Soc. 41(2):176-81
2. 2. Van Snick J. 1990. Interleukin-6: an overview. Annu. Rev. Immunol. 8:253-78
3. 3. Akira S, Taga T, Kishimoto T. 1993. Interleukin-6 in biology and medicine. Adv. Immunol. 54:1-78
4. 4. Weissenbach J, Chernajovsky Y, Zeevi M, et al. 1980. Two interferon mRNA in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc. Natl. Acad. Sci. USA 77:7152-56
5. 5. Sehgal PB, Greininger G, Tosato G. 1989. Acute phase and immune responses: interleukin-6. Ann. NY Acad. Sci. 557:1-583
6. 6. Hirano T, Teranishi T, Lin BH, Onoue K. 1984. Human helper T cell factor(s). IV. Demonstration of a human late-acting B cell differentiation factor acting on Staphylococcus aureus Cowen I-stimulated B cells. J. Immunol. 133:798-802
7. 7. Muraguchi A, Hirano T, Tang B, et al. 1988. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J. Exp. Med. 67:332-44
8. 8. Taga T, Kawanishi Y, Hardy TT, et al. 1987. Receptors for B cell stimulatory factor 2. J. Exp. Med. 166:967-81
9. 9. Ambrosino DM, Delaney NR, Shamberger RC. 1990. Human polysaccharide-specific B cells are responsive to pokeweed mitogen and IL-6. J. Immunol. 144:1221-26
10. 10. Takatsuki F, Okano A, Suzuki C, et al. 1988. Human recombinant IL-6/B cell-stimulatory factor 2 augments murine antigen-specific antibody responses in vitro and in vivo. J. Immunol. 141:3072-77
11. 11. Uyttenhove C, Coulie PG, Van Snick J. 1988. T cell growth and differentiation induced by interleukin HP1/IL-6, the murine hybridoma/plasmacytoma growth factor. J. Exp. Med. 167:1414-27
12. 12. Lotz M, Jirik F, Kabouridis R, et al. 1988. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J. Exp. Med. 167:1253-58
13. 13. Helle M, Brakenhoff JPJ, DeGroot ET, Aarden LA. 1988. InterIeukin-6 is involved in interleukin-1-induced activities. Eur. J. Immunol. 18:957-59
14. 14. Okada M, Kitahara N, Kishimoto S, et al. 1988. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J. Immunol. 141:1543-49
15. 15. Renauld JC, Vink A, Van Snick J. 1989. IL1 and IL6 in CTL induction-accessory signals in murine cytolytic T cell responses: dual requirement for IL1 and IL6. J. Immunol. 143:1894-98
16. 16. Luger TA, Krutman J, Kirnbauer T, et al. 1989. IFNβ/IL-6 augments the activity of human natural killer cells. J. Immunol. 143:1206-9
17. 17. Kurihara N, Bertolini D, Suda T, et al. 1990. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J. Immunol. 144:4226-30
18. 18. Tamura T, Udagawa N, Takahashi N, et al. 1993. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc. Natl. Acad. Sci. USA 90:11924-28
19. 19. Passeri G, Girasole G, Markus T, et al. 1991. 17B-estradiol regulates IL-6 production and osteoclast development in murine calvaria cell cultures. J. Bone Miner. Res. 6:S263 (Suppl. 1)
20. 20. Girasole G, Jilka RL, Passeri G, et al. 1992. 17β-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J. Clin. Invest. 89(3): 883-91
21. 21. Jilka RL, Hangoc C, Girasole G, et al. 1992. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 257:88-91
22. 22. Miyaura C, Kusano K, Masuzawa T, et al. 1995. Endogenous bone-resorbing factors in estrogen deficiency: cooperative effects of IL-1 and IL-6. J. Bone Miner. Res. 10:1365-73
23. 23. Poli V, Balena R, Fattori E, et al. 1994. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13:1189-96
24. 24. Tabibzadeh S, Kong QF, Babaknia A, May LT. 1995. Progressive rise in the expression of interleukin-6 in human endometrium during menstrual cycle is initiated during the implantation window. Mol. Hum. Reprod. 1:2793-99
25. 25. Tabibzadeh SS, Santhanam U, Sehgal PB, May LT. 1989. Cytokine-induced production of IFN-β2/IL-6 by freshly explanted human endometrial stromal cells. Modulation by estradiol-17β. J. Immunol. 142(9):3134-39
26. 26. Hakovirta H, Syed V, Jegou B, Parvinen M. 1995. Function of interleukin-6 as an inhibitor of meiotic DNA synthesis in the rat seminiferous epithelium. Mol. Cell. Endocrinol. 108:193-98
27. 27. Krueger JG, Krane JF, Carter DM, Gottlieb AB. 1990. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J. Invest. Dermatol. 94:135-140 (Suppl.)
28. 28. Grossman RM, Kreuger J, Yourish D, et al. 1989. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl. Acad. Sci. USA 86:6367-71
29. 29. Yoshizaki K, Nishimoto N, Matsumoto K, et al. 1990. Interleukin-6 and expression of its receptor on epidermal keratinocytes. Cytokines 2:381-87
30. 30. Navarro S, Devili N, LeCouedic JP, et al. 1991. Interleukin-6 and its receptor are expressed by human megakaryocytes: in vitro effects on proliferation and endo-replication. Blood 77:461-71
31. 31. Sun WH, Binkley N, Bidwell DW, Ershler WB. 1993. The influence of recombinant human interleukin-6 on blood and immune parameters in middle-aged and old rhesus monkeys. Lymphokine Cytokine Res. 12(6):449-55
32. 32. Hill RJ, Warren MK, Levin J. 1990. Stimulation of thrombopoiesis in mice by human recombinant interleukin-6. J. Clin. Invest. 85:1242-47
33. 33. Hama T, Miyamoto M, Tsukui H, et al. 1989. Interleukin-6 as a neurotrophic factor for promoting the survival of cultured basal forebrain cholinergic neurons from postnatal rats. Neurosci. Lett. 104:340-44
34. 34. Satoh T, Nakamura S, Taga T, et al. 1988. Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6. Mol. Cell. Biol. 8:3546-49
35. 35. Sehgal PB, Zilberstein A, Ruggieri MR, et al. 1986. Human chromosome 7 carries the β2 interferon gene. Proc. Natl. Acad. Sci. USA 83:8957-61
36. 36. Zilberstein A, Ruggieri R, Korn JH, Revel M. 1986. Structure and expression of cDNA and genes for human interferon b-2, a distinct species inducible by growth-stimulatory cytokines. EMBO J. 5:2529-37
37. 37. Yasukawa K, Hirano T, Watanabe Y, et al. 1987. Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J. 6(10):2939-45
38. 38. Simpson RJ, Moritz RL, Rubira MR, Van Snick J. 1988. Murine hybridoma/ plasmacytoma growth factor: complete amino acid sequence and relation to human interleukin-6. Eur. J. Biochem. 176:187-97
39. 39. Sehgal PB, Walther Z, Tamm I. 1987. Rapid enhancement of β2-interferon/B-cell differentiation factor BSF-2 gene expression in human fibroblasts by diacylglycerols and the calcium ionophore A23187. Proc. Natl. Acad. Sci. USA 84:3633-35
40. 40. Zhang Y, Lin J-X, Vilcek J. 1988. Synthesis of interleukin-6 (interferon-β2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP. J. Biol. Chem. 263:6177-82
41. 41. Zhang Y, Lin J-X, Yip YK, Vilcek J. 1988. Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin-1 in human fibroblasts: role in the induction of interleukin-6. Proc. Natl. Acad. Sci. USA 85:6802-6
42. 42. Zhang Y, Broser M, Rom WN. 1994. Activation of the interleukin 6 gene by Mycobacterium tuberculosis or lipopolysaccharide is mediated by nuclear factors NF-IL6 and NF-kappa B. Proc. Natl. Acad. Sci USA 91(6):2225-29
43. 43. Muraoka O, Kaisho T, Tanabe M, Hirano T. 1993. Transcriptonal activation of the interleukin-6 gene by HTLV-1 p40tax through an NF-κB-like binding site. Itnmunol. Lett. 37:159-65
44. 44. Yamashita I, Katamine S, Moriuchi R, et al. 1994. Transactivation of the human interleukin-6 gene by human T-lymphotropic virus type 1 Tax protein. Blood 84(5):1573-78
45. 45. Yan SF, Tritto I, Pinsky D, et al. 1995. Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6. J. Biol. Chem. 270(19): 11463-71
46. 46. Dendorfer U, Oettgen P, Libermann TA. 1994. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol. Cell. Biol. 14(7): 4443-54
47. 47. Scala G, Ruocco MR, Ambrosino C, et al. 1994. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J. Exp. Med. 179(3):961-71
48. 48. Brach MA, Gruss HJ, Kaisho T, et al. 1993. Ionizing radiation induces expression of interleukin 6 by human fibroblasts involving activation of nuclear factor-kappa B. J. Biol. Chem. 268(12): 8466-72
49. 49. Margulies L, Sehgal PB. 1993. Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBPβ (NF-IL6) activity by p534 species. J. Biol. Chem. 268:15096-100
50. 50. Janaswami PM, Kalvakolanu DV, Zhang Y, Sen GC. 1992. Transcriptional repression of interleukin-6 gene by adenoviral E1A proteins. J. Biol. Chem. 267(34):24886-91
51. 51. Brach MA, de Vos S, Arnold C, et al. 1992. Leukotriene B4 transcriptionally activates interleukin-6 expression involving NK-chi B and NF-IL6. Eur. J. Immunol. 22(10):2705-11
52. 52. Gruss HJ, Brach MA, Herrmann F. 1992. Involvement of nuclear factor-kappa B in induction of the interleukin-6 gene by leukemia inhibitory factor. Blood 80(10):2563-70
53. 53. Yee CS, Messner HA, Minden MD. 1991. Regulation of interleukin-6 expression in the lymphoma cell line OCI-LY3. J. Cell. Physiol. 148:426-29
54. 54. Zhang Y, Lin J-X, Vilcek J. 1990. Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a kappa B-like sequence. Mol. Cell. Biol. 10:3818-23
55. 55. Shimizu H, Mitomo K, Watanabe T, et al. 1990. Involvement of a NF-κB-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines. Mol. Cell. Biol. 10:561-68
56. 56. Tanabe O, Akira S, Kamiya T, et al. 1988. Genomic structure of the murine IL-6 gene: high degree of conservation of potential regulatory sequences between mouse and human. J. Immunol. 141:3875-81
57. 57. Woloski BMRNJ, Smith EM, Meyer WJ III, et al. 1985. Corticotropin-releasing activity in monokines. Science 230: 1035-37
58. 58. Kohase M, Henriksen-DiStefano D, May LT, Vilcek J. 1987. Dexamethasone inhibits feedback regulation of the mitogenic activity of tumor necrosis factor, interleukin-1 and epidermal growth factor in human fibroblasts. J. Cell. Physiol. 132:271-78
59. 59. Feyen HJM, Elford P, Ki Padova FE, Trechsel U. 1989. Interleukin-6 is produced by bone and modulated by parathyroid hormone. J Bone Miner. Res. 4:633-38
60. 60. Ray A, LaForge KS, Sehgal PB. 1990. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol. Cell. Biol. 10:5736-16
61. 61. Ray A, LaForge KS, Sehgal PB. 1991. Represser to activator switch by mutations in the glucocorticoid receptor: Is direct DNA binding necessary? Proc. Natl. Acad. Sci. USA 88(16):7086-90
62. 62. Ray A, Prefontaine KE. 1994. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA 91(2):752-56
63. 63. Deleted in proof
64. 64. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. 1995. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 270:283-86
65. 65. Auphan N, DiDonato A, Rosette C, 1995. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270:286-290
66. 66. Navarra P, Tsagarakis S, Fana M, et al. 1990. Interleukm-1 and -6 stimulate the release of corticotropin-releasing hormone from rat hypothalamus in vitro via eicosanoid cyclooxygenase pathway. Endocrinology 128:37-44
67. 67. Lyson K, Milenkovic K, McCann SM. 1991. The stimulatory effect of interleukin-6 on corticotropin-releasing factor and thyrotropin-releasing hormone secretion in vitro. Prog. Neuroendocrinol. Immunol. 4:161-65
68. 68. Tabibzadeh SS, Poubouridis D, May LT, Sehgal PB. 1989. Interleukin-6 immunoreactivity in human tumors. Am. J. Pathol. 135:427-33
69. 69. Kania DM, Binkley N, Checovich M, et al. 1995. Elevated plasma levels of interleukin-6 in postmenopausal women do not correlate with bone density. J. Am. Geriatr. Soc. 43(3):236-39
70. 70. Ralston SH. 1994. Analysis of gene expression in human bone biopsies by polymerase chain reaction: evidence for enhanced cytokine expression in postmenopausal osteoporosis. J. Bone Miner. Res. 9:883-90
71. 71. Daynes RA, Araneo BA, Ershler WB, et al. 1993. A dysregulation in the production of interleukin-6 with normal aging: probable linkage to the age associated depression in dehydroepiandrosterone (DHEA) and its sulfated derivative. J. Immunol. 150:5219-30
72. 72. Pacifici R, Brown C, Puscheck E, et al. 1991. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc. Natl. Acad. Sci. USA 88:5134-38
73. 73. Pioli G, Basini G, Pedtazzoni M, et al. 1992. Spontaneous release of interleukin-1 and interleukin-6 by peripheral blood mononuclear cells after oophorectomy. Clin. Sci. 83:503-7
74. 74. Kassem M, Harris SA, Spelsberg TC, Riggs BL. 1996. Estrogen inhibits interleukin-6 production and gene expression in a human osteoblastic cell line with high levels of estrogen receptor. J. Bone Miner. Res. 11:193-99
75. 75. Chaudhary LR, Spelsberg TC, Riggs BL. 1992. Production of various cytokines by normal human osteoblast-like cells in response to interleukin-1β and tumor necrosis factor-α: lack of regulation by 17β-estradiol. Endocrinology 130:2528-34
76. 76. Kitazawa R, Kimble RB, Vannice JL, et al. 1994. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J. Clin. Invest. 94:2397-406
77. 77. Rickard D, Russel G, Gowen M. 1992. Oestradiol inhibits the release of tumor necrosis factor but not interleukin-6 from adult human osteoblasts in vitro. Osteoporosis Int. 2:94-102
78. 78. Rifas L, Kenney JS, Marcelli M, et al. 1995. Production of interleukin-6 in human osteoblasts and human bone marrow stromal cells: evidence that induction by interleukin-1 and tumor necrosis factor-a is not regulated by ovarian steroids. Endocrinology 136:4056-67
79. 79. Pottratz ST, Bellido T, Mocharla H, et al. 1994. 17β-Estradiol inhibits expression of human promoter-reporter constructs by a receptor-dependent mechanism. J. Clin. Invest. 93(3):944-50
80. 80. Ray A, Prefontaine KE, Ray P. 1994. Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J. Biol. Chem. 269(17):12940-46
81. 81. Deleted in proof
82. 82. Stein B, Yang MX. 1995. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/ EBPβ. Mol. Cell. Biol. 15(9):4971-79
83. 83. Sun WH, Keller ET, Stabler BS, Ershler WB. 1998. Estrogen inhibits phorbol ester-induced IκBα transcription and protein degradation. Biochem. Biophys. Res. Commun. 244:691-95
84. 84. Galien R, Evans HF, Garcia T. 1996. Involvement of CCAAT/enhancer binding protein and nuclear factor-κB binding sites in interleukin-6 promoter inhibition by estrogens. Mol. Endocrinol. 10:713-22
85. 85. Bellido T, Jilka RL, Boyce BF, et al. 1995. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J. Clin. Inv. 95(6):2886-95
86. 86. Keller ET, Chang C, Ershler WB. 1996. Inhibition of NFκB activity through maintenance of IκBα levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J. Biol. Chem. 271:26267-75
87. 87. Zhang J, Keller ET, Pugh TD, et al. 1998. Orchiectomy increases bone marrow interleukin-6 expression in mice. Calcif. Tissue Int. 62:219-26
88. 88. Smith EP, Boyd J, Frank GR, et al. 1994. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 331:1056-61
89. 89. Yamasaki K, Taga T, Hirata Y, et al. 1988. Cloning and expression of the human interleukin-6 (BSF-2/IFNβ 2) receptor. Science 241:825-28
90. 90. Schooltink H, Stoyan T, Lenz D, et al. 1991. Structural and functional studies on the human hepatic interleukin-6 receptor. Biochem. J. 277:659-64
91. 91. Kluck PMC, Wiegant J, Hansen RPM, et al. 1993. The human interleukin-6 receptor a chain gene is localized on chromosome 1 band q21. Hum. Genet. 90:542-44
92. 92. Bazan JF. 1989. A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor β-chain. Biochem. Biophys. Res. Commun. 164:788-95
93. 93. Cosman D, Lyman SD, Idzerda RL, et al. 1990. A new cytokine receptor superfamily. Trends Biol. Sci. 15:265-70
94. 94. Taga T, Hibi M, Murakami M, et al. 1992. Interleukin-6 receptor and signals. Chem. Immunol. 1992; 51:181-204
95. 95. Taga T, Hibi M, Hirata Y, et al. 1989. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp 130. Cell 58:573-81
96. 96. Murakami M, Hibi M, Nakagawa N, et al. 1993. IL-6-induced homodimerization of gp 130 and associated activation of a tyrosine kinase. Science 260:1808-10
97. 97. Ward LD, Howlett GJ, Discolo G, et al. 1994. High affinity interleukin-6 receptor is a hexameric consisting of two molecules each of interleukin-6, receptor, and gp-130. J. Biol. Chem. 269:23286-89
98. 98. Novick D, Engelmann H, Wallach D, Rubinstein M. 1989. Soluble cytokine receptors are present in normal human urine. J. Exp. Med. 170:1409-14
99. 99. Lust JA, Jelinek DF, Donovan KA, et al. 1994. Sequence, expression and function of an mRNA encoding of the human interleukin-6 receptor (sIL-6R). Curr. Top. Microbiol. Immunol. 194:199-205
100. 100. Mullberg J, Schooltink J, Stoyan T, et al. 1993. The soluble interleukin-6 receptor is generated by shedding. Eur. J. Immunol. 23:473-80
101. 101. Nakajima T, Yamamoto S, Cheng M, et al. 1992. Soluble interleukin-6 receptor is released from receptor-bearing cell line in vitro. Jpn. J. Cancer Res. 83:373-78
102. 102. Snyers L, Fontaine V, Content J. 1989. Modulation of interleukin-6 receptors in human cells. Ann. NY Acad. Sci. 557:388-93
103. 103. Lin SC, Yamate T, Taguchi Y, et al. 1997. Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow. J. Clin. Invest. 100:1980-90
104. 104. Tang B, Matsuda T, Akira S, et al. 1991. Age-associated increase in interleukin 6 in MRL/lpr mice. Int. Immunol. 3(3): 273-78
105. 105. Suzuki H, Yasukawa K, Saito T, et al. 1993. Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal. Eur. J. Immunol. 23(5):1078-82
106. 106. Effros RB, Svoboda K, Walford RL. 1993. Influence of age and caloric restriction on macrophage IL-6 and TNF production. Lymphokine Cytokine Res. 10(5):347-51
107. 107. Zhou D, Chrest FJ, Adler W, et al. 1993. Increased production of TGF-beta and IL-6 by aged spleen cells. Immunol. Lett. 36(1):7-11
108. 108. Foster KD, Conn CA, Kluger MJ. 1992. Fever, tumor necrosis factor, and interleukin-6 in young, mature, and aged Fischer 344 rats. Am. J. Physiol. 262: R211-15
109. 109. Wei J, Xu H, Davies JL, Hemmings GP. 1992. Increase of plasma IL-6 concentrations with age in healthy subjects. Life Sci. 51:1953-56
110. 110. Goya RG, Gagnerault MC, De Moraes, et al. 1992. In vivo effects of growth hormone on thymus function in aging mice. Brain Behav. Immunol. 6:341-54
111. 111. Ershler WB, Sun WH, Binkley N, et al. 1993. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res. 12(4):225-30
112. 112. Sindermann J, Kruse A, Frercks HJ, et al. 1993. Investigations of the lymphokine system in elderly individuals. Mech. Ageing Dev. 70(1-2):149-59
113. 113. McKane R, Khosla S, Peterson J. 1993. Effect of age and menopause on serum interleukin-6 levels in women. J. Bone Miner. Res. 8:S157 (Suppl.)
114. 114. Fagiolo U, Cossarizza A, Scala E, et al. 1993. Increased cytokine production in mononuclear cells of healthy elderly people. Eur. J. Immunol. 23(9):2375-78
115. 115. Liao Z, Caucino JA, Schnipper SM, et al. 1993. Increased urinary cytokines in the elderly. Aging Immunol. Infect. Dis. 4:139-53
116. 116. Kawano M, Hirano T, Matsuda T, et al. 1988. Automne generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 332:83-85
117. 117. Klein B, Zhang X, Jourdan M, et al. 1989. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73(2):517-26
118. 118. Asaoku H, Kaeano M, Iwato K, et al. 1988. Decrease in BSF-2/IL-6 response in advanced cases of multiple myeloma. Blood 72:429-32
119. 119. Kato H, Kinoshita T, Suzuki S, et al. 1996. Elevated serum interleukin-6 (IL-6) is derived from neoplastic lymphoid cells in patients with B-cell non-Hodgkin's lymphoma: correlation with extent of IL-6 expression and serum concentration. Er. J. Haematol. 92(4):1014-21
120. 120. Kurzrock R, Redman J, Cabanillas F, et al. 1993. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res. 53:2118-22
121. 121. Lavabre-Bertrand T, Exbrayat C, Liautard J, et al. 1995. Detection of membrane and soluble interleukin-6 receptor, in lymphoid malignancies. Br. J. Haemaol. 91(4):871-77
122. 122. Yoshizaki K, Matsuda T, Nishimoto N, et al. 1989. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74:1360-67
123. 123. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. 1990. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J. Clin. Invest. 86:592-99
124. 124. Gause A, Scholz R, Klein S, et al. 1991. Increased levels of circulating interleukin-6 in patients with Hodgkin's disease. Hematol. Oncol. 9(6):307-13
125. 125. Yamamura M, Honda M, Yamada Y, et al. 1996. Increased levels of interleukin-6 (IL-6) in serum and spontaneous in vitro production of IL-6 by lymph node mononuclear cells of patients with angioimmunoblastic lymphadenopathy with dyspioteinemia (AILD) and clinical effectiveness of cyclosporin A. Leukemia 10(9):1504-8
126. 126. Kim SS, Chung SM, Choi IP, Byun KH. 1995. Expression of interleukin-6 in polymorphic reticulosis - immunohistochemical study. J. Korean Med. Sci. 10(5):324-28
127. 127. Stasi R, Zinzani L, Galieni P, et al. 1995. Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma. Eur. J. Haematol. 54(1):9-17
128. 128. Seymour JF, Talpaz M, Cabanillas F, et al. 1995. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J. Clin. Oncol. 13(3):575-82
129. 129. Kanno H, Yasunaga Y, Iuchi K, et al. 1996. Interleukin-6 mediated growth enhancement of cell lines derived from pyothorax-associated lymphoma. Lab. Invest. 75(2):167-73
130. 130. Freeman GJ, Freedman AS, Rabinowe SN, et al. 1989. Interleukin 6 gene expression in normal and neoplastic B cells. J. Clin. Invest. 83:1512-18
131. 131. Yee C, Biondi A, Wang XH, et al. 1989. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood 74(2):798-804
132. 132. Takeshita M, Sumiyoshi Y, Masuda, Y, et al. 1993. Cytokine (interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor alpha, and interleukin-6)-possessing cells in lymph nodes of malignant lymphoma. Pathol. Res. Pract. 189(1):18-25
133. 133. Voorzanger N, Touitou R, Garcia E, et al. 1996. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res. 56(23): 5499-505
134. 134. Frith CH, Davis TM, Zolotor LA, Townsend JW. 1980. Histiocytic lymphoma in the mouse. Leuk. Res. 4:651-62
135. 135. Volk MJ, Pugh TD, Kim MJ, et al. 1993. Dietary restriction from middle age attenuates age-associated lymphoma development and EL-6 dysregulation in C57BL/6 mice. Cancer Res. 54:3054-63
136. 136. Weindruch R, Walford RL. 1988. The Retardation of Aging and Disease by Dietary Restriction. Springfield, IL: Thomas
137. 137. Peled A, Tzehoval E, Haran-Ghera N. 1995. Role of cytokines in termination of the B cell lymphoma dormant state in AKR mice. Leukemia 9(6):1095-101
138. 138. Hubert DM, Kopf M, Mock BA, et al. 1995. Interleukin-6 is essential for in vivo development of B lineage neoplasms. J. Exp. Med. 182(1):243-48
139. 139. Zhang XG, Klein B, Bataille R. 1989. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 74:11-13
140. 140. Gaillard JP, Bataille R, Brailly H, et al. 1993. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur. J. Immunol. 23:820-24
141. 141. Solary E, Guiguet M, Zeller V, et al. 1992. Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumor cell mass parameters in multiple myeloma. Am. J. Hematol. 39:163-71
142. 142. Bataille R, Jourdan M, Zhang XG, Klein B. 1989. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J. Clin. Invest. 84:2008-11
143. 143. Ballester OF, Moscinski LC, Lyman GH, et al. 1994. High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. Blood 83:1903-8
144. 144. Stauder R, Van Driel M, Schwarzler C, et al. 1996. Different CD44 splicing patterns define prognostic subgroups in multiple myeloma. Blood 88(8):3101-8
145. 145. Klein B, Lu ZY, Gallard JP, et al. 1992. Inhibiting EL-6 in human multiple myeloma. Curr. Top. Microbiol. Immunol. 182:237-43
146. 146. Klein B, Lu ZY, Bataille R. 1992. Clinical applications of IL6 inhibitors. Res. Immunol. 143(7):774-76
147. 147. Klein B, Wijdenes J, Zhang XG, et al. 1991. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 5:1198-204
148. 148. Sipe JD, Bartle LM, Loose LD. 1992. Modification of proinflammatory production by the antirheumatic agents Tenidap and Naproxen. A possible correlate with the clinical acute phase response. J. Immunol. 148:480-84
149. 149. Wagge A, Slupphaug G, Shalaby R. 1990. Glucocorticoids inhibit production of IL-6 from monocytes, endothelial cells and fibroblasts. Eur. J. Immunol. 20:2439-43
150. 150. Keller ET, Ershler WB. 1995. Effect of IL-6 receptor antisense oligodeoxynucleotides on in vitro proliferation of myeloma cells. J. Immunol. 154:4091-98
151. 151. Manolagas SC, Jilka RL. 1995. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med. 332(5):305-11
152. 152. Lorenzo JA. 1991. The role of cytokines in the regulation of local bone resorption. Crit. Rev. Immunol. 11:195-213
153. 153. Bellido T, Girasole G, Passeri G, et al. 1994. Sex steroids regulate the expression of the gp130 transduction pathway by bone marrow and bone cells. Bone Miner. 25(S1):S39
154. 154. Fang MA, Hahn TJ. 1991. Effects of interleukin-6 on cellular function in UMR-106-01 osteoblast-like cells. J. Bone Miner. Res. 6:133-39
155. 155. Taguchi Y, Yamate T, Mocharia H, et al. 1996. Interleukin-6 induces osteoblast differentiation in uncommitted embryonic fibroblasts (EF). J. Bone Miner. Res. 11:S101 (Suppl.) (Abstr.)
156. 156. Ishimi Y, Miyaura C, Jin CH, et al. 1990. IL-6 is produced by osteoblasts and induces bone resorption. J. Immunol. 145:3297-303
157. 157. Green H, Schotland S, Sella Z, Kleeman CR. 1994. Interleukin-6 attenuates agonist-mediated calcium mobilization in murine osteoblastic cells. J. Clin. Invest. 93:2340-50
158. 158. Littlewood AJ, Aarden LA, Evans DB, et al. 1991. Human osteoblastlike cells do not respond to interleukin-6. J. Bone Miner. Res. 6:141-48
159. 159. Greenfield EM, Shaw SM, Gornik SA, Banks MA. 1995. Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J. Clin. Invest. 96:1238-44
160. 160. Löwik CWGM, van der Pluijm G, Bloys H, et al. 1989. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem. Biophys. Res. Commun. 162:1546-52
161. 161. Rahman S, Bunning RAD, Dobson PRM, et al. 1992. Bradykinin stimulates the production of prostaglandin E2 and interleukin-6 in human osteoblast-like cells. Biochim. Biophys. Acta 1135:97-102
162. 162. Zheng MH, Wood DJ, Wysocki S, et al. 1994. Recombinant human bone morphogenetic protein-2 enhances expression of interleukin-6 and transforming growth factor-β1 genes in normal human osteoblast-like cells. J. Cell. Physiol. 159:76-82
163. 163. Al-Humidan A, Ralston SH, Hughes DE, et al. 1991. Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae. J. Bone Miner. Res. 6:3-8
164. 164. Flanagan AM, Stow MD, Williams R. 1995. The effect of interleukin-6 and soluble interleukin-6 receptor protein on the bone resorptive activity of human osteoclasts generated in vitro. J. Pathol. 176:289-97
165. 165. Roodman GD, Kurihara N, Ohsaki Y, et al. 1992. Interleukin-6: a potential autocrine/paracrine factor in Paget's disease of bone. J. Clin. Invest. 89:46-52
166. 166. Black KS, Mundy GR, Garrett IR. 1991. Interleukin-6 causes hypercalcemia in vivo, and enhances the bone resorbing potency of interleukin-1 and tumor necrosis factor by two orders of magnitude in vitro. J. Bone Miner. Res. 6:S271 (Suppl.)
167. 167. Ohsaki Y, Takahashi S, Scarcez T, et al. 1992. Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone. Endocrinology 131: 2229-34
168. 168. Mrak RE, Sheng JG, Griffin WS. 1995. Glial cytokines in Alzheimer's disease review and pathogenic implications. Hum. Pathol. 26:816-23
169. 169. Bauer J, Ganter U, Strauss S, et al. 1992. The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. Res. Immunol. 143(6):650-57
170. 170. Vandenabelle P, Fiers W. 1991. Is amyloidogenesis during Alzheimer's disease due to an IL-1/IL-6-mediated "acute phase response" in the brain? Immunol. Today 12:217-19
171. 171. Ganter U, Strauss S, Jonas V, et al. 1991. Alpha-2 macroglobulin synthesis in interleukin-6 stimulated human neuronal (SH-SY5Y neuroblastoma) cells. FEBS Lett. 282:127-31
172. 172. Strauss S, Bauer J, Ganter U, et al. 1992. Detection of interleukin-6 and a2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab. Invest. 66:223-30
173. 173. Bauer J, Strauss S, Schreiter-Gasser U, et al. 1991. Interleukin-6 and α2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 285:111-14
174. 174. Abraham CR, Shirahama T, Potter H. 1990. α1-Antichymotrypsin is associated solely with amyloid deposits containing the β-protein. Amyloid and cell localization of α1-antichymotrypsin. Neurobiol. Aging 11:123-26
175. 175. Wood JA, Wood PL, Ryan R, et al. 1993. Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res. 629(2):245-52
176. 176. Blum-Degen D, Muller T, Kuhn W, et al. 1995. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's disease and de novo Parkinson's disease patients. Neurosci. Lett. 202(1-2):17-20
177. 177. Yamada K, Kono K, Umegaki H, et al. 1995. Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia. Neurosci. Lett. 186(2-3):219-21
178. 178. Chao CC, Ala TA, Hu S, et al. 1994. Serum cytokine levels in patients with Alzheimer's disease. Clin. Diagn. Lab. Immunol. 1(4):433-36
179. 179. van Duijn CM, Hofman A, Nagelkerken L. 1990. Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease. Neurosci. Lett. 108:350-54
180. 180. Cadman ED, Witte DG, Lee CM. 1994. Regulation of the release of interleukin-6 from human astrocytoma cells. J. Neurochem. 63(3):980-87
181. 181. Sebire G, Emilie D, Wallon C, et al. 1993. In vitro production of IL-6, IL-1β, and tumor necrosis factor-α by human embryonic microglial and neural cells. J. Immunol. 150:1517-23
182. 182. Del Bo R, Angeretti N, Lucca E, et al. 1995. Reciprocal control of inflammatory cytokines, IL-1, IL-6 and beta-amyloid production in cultures. Neurosci. Lett. 188(1):70-74
183. 183. Hull M, Strauss S, Berger M, et al. 1996. The participation of interleukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer's disease. Behav. Brain Res. 78(1):37-41
184. 184. Huell M, Strauss S, Volk B, et al. 1995. Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients. Acta Neuropathol. 89(6):544-51
185. 185. Cacabelos R, Franco-Maside A, Alvarez XA. 1991. Interleukin 1 in Alzheimer's disease and multi-infarct dementia: neurophysiological correlations. Methods Exp. Clin. Pharmacol. 13:703-8
186. 186. Huberman M, Sredni B, Stern L, et al. 1995. IL-2 and IL-6 secretion in dementia: correlation with type and severity of disease. J. Neurol. Sci. 130(2):161-64
187. 187. Shalit F, Sredni B, Stern L, et al. 1994. Elevated interleukin-6 secretion levels by mononuclear cells of Alzheimer's patients. Neurosci. Lett. 174(2):130-32
188. 188. Fattori E, Lazzaro D, Musiani P, et al. 1995. IL-6 expression in neurons of transgenic mice causes reactive astrocytosis and increase in ramified microglial cells but no neuronal damage. Eur. J. Neurosci. 7(12):2441-49
189. 189. Bellinger FP, Madamba SG, Campbell IL, Siggins GR. 1995. Reduced long term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6. Neurosci. Lett. 198(2):95-98
190. 190. Brett FM, Mizisin AP, Powell HC, Campbell IL. 1995. Evolution of neuropathologic abnormalities associated with blood brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. J. Neuropathol. Exp. Neurol. 54(6):766-75
191. 191. Chiang CS, Stalder A, Samimi A, Campbell IL. 1994. Reactive gliosis as a consequence of interleukin-6 expression in the brain: studies in transgenic mice. Dev. Neurosci. 16(3-4):212-21
192. 192. Steffensen SC, Campbell IL, Henriksen SJ. 1994. Site-specific hippocampal pathophysiology due to cerebral overexpression of interleukin-6 in transgenic mice. Brain Res. 652(1): 149-53
193. 193. Campbell IL, Abraham CR, Masilaah E, et al. 1993. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin-6. Proc. Natl. Acad. Sci. USA 90(21): 10061-65
194. 194. Kawas C, Resnick S, Morrison A, et al. 1997. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 48(6):1517-21
195. 195. Stewart WF, Kawas C, Corrada M, Metter EJ. 1997. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48(3):626-32
196. 196. Binkley NC, Sun WH, Checovich MM, et al. 1994. Effects of recombinant human interleukin-6 administration on bone in rhesus monkeys. Lymphokine Cytokine Res. 13:221-26
197. 197. Cohen HJ, Pieper CF, Harris T, et al. 1997. The association of plasma IL-6 levels with functional disability in community dwelling elderly. J. Gerontol. Med. Sci. 52:M201-8